UCB reports sustained seizure reduction with FINTEPLA in LGS patients

The post hoc analysis examined 151 patients who completed a 12-month open-label extension study following an initial Phase 3 trial. Researchers compared those who switched from placebo to FINTEPLA against those who maintained the medication throughout both phases. Results indicated that seizure frequency in the switch group dropped by 32.1% within the first month, reaching a 48.2% reduction by months four through six. This trajectory aligned closely with the outcomes observed in patients who received the drug from the study's inception.

Beyond seizure control, the study highlighted improvements in global functioning as assessed by investigators and caregivers. Hugo Xi, head of medical for epilepsy and rare syndromes at UCB, noted that these findings provide clinicians with clearer expectations regarding early response and the benefits of long-term dose titration for this challenging condition. The safety profile remained consistent with previous data; while common adverse events like decreased appetite and somnolence were reported early in treatment, their incidence declined over time.